Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant NabPE With or Without Serplulimab for Early-stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Breast cancer-an Observational Real-world Study.

NCT06781281 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT06781281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06781281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant NabPE With or Without Serplulimab for Early-stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Breast cancer-an Observational Real-world Study.
Lead sponsor
Henan Cancer Hospital
Phase
Observational
Overall status
Recruiting
Start date
December 4, 2024
Completion date
November 28, 2030
Enrollment
709 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer invasive